CAR-T cell therapy has emerged as a promising cancer immunotherapy treatment, showing impressive results in blood cancers. However, significant challenges remain in its application to solid tumors. Our proprietary "Eumbody System" technology enables the efficient creation of highly effective chimeric antigen receptors (CARs), overcoming current limitations and paving the way for next-generation CAR-T cells. This breakthrough technology aims to deliver innovative therapeutic solutions for patients with solid tumors, initially aiming to develop CAR-T cell therapy for the treatment of glioblastoma.